Plain-English translation of NCT07115043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called that works by boosting your immune system's ability to fight cancer. Researchers want to see if this medication is safe and effective when given alone or combined with another cancer treatment. The study will enroll about 60 participants with various advanced cancers that haven't responded well to standard treatments.
Many people with advanced cancers need new treatment options because their cancers stop responding to existing therapies. This medication is designed to work differently by directly activating immune cells called CD8 cells, which are natural cancer fighters in your body.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through an intravenous infusion (IV line into your arm) at the study clinic. Depending on which study arm you join, you may receive the medication alone or in combination with another treatment. You'll have regular visits for blood tests, imaging scans, and physical exams to monitor how your cancer responds and watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States